Article info
PDFLetter
Efficacy of JAK 1/2 inhibition in the treatment of diffuse non-scarring alopecia due to systemic lupus erythematosus
- Correspondence to Dr Keisuke Maeshima, Rheumatology, Faculty of Medicine Graduate School of Medicine, Oita University, Yufu 879-5593, Japan; maeshima{at}oita-u.ac.jp
Citation
Efficacy of JAK 1/2 inhibition in the treatment of diffuse non-scarring alopecia due to systemic lupus erythematosus
Publication history
- Received October 31, 2019
- Revised December 11, 2019
- Accepted December 12, 2019
- First published January 3, 2020.
Online issue publication
May 12, 2021
Article Versions
- Previous version (15 April 2020).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.